Last Updated:
10 Mar 2026, 03:29:56 PM (IST)
Aarti Pharmalabs Limited
NSE: AARTIPHARM BSE: AARTIPHARM
NSE
686.70
5.65 (0.83%)
Prev Close
681.05
Open Price
690.35
Volume
118,363
Today Low / High
681.05 / 695
52 WK Low / High
574.45 / 971
Range
652 - 721
BSE
685.55
4.05 (0.59%)
Prev Close
681.5
Open Price
684.95
Volume
7,390
Today Low / High
681.7 / 695
52 WK Low / High
557.2 / 971.5
Range
651 - 720
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 686.7 (target range: 652 - 721), reflecting a change of 5.65 (0.8296%). On the BSE, it is listed at 685.55 (target range: 651 - 720), showing a change of 4.05 (0.59428%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Mar
681.00
3.63%
27 Feb
718.25
0.76%
26 Feb
709.00
1.51%
Aarti Pharmalabs Limited Graph
Aarti Pharmalabs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aarti Pharmalabs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 686.70, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 685.55 | 692.41 | 623.16 - 761.65 |
| 699.26 | 559.41 - 839.11 | ||
| 706.12 | 494.28 - 917.95 | ||
| Bearish Scenario | 685.55 | 678.69 | 610.83 - 746.56 |
| 671.84 | 537.47 - 806.21 | ||
| 664.98 | 465.49 - 864.48 |
Overview of Aarti Pharmalabs Limited
ISIN
INE0LRU01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
199,188
Market Cap
63,974,324,918
Last Dividend
4
Official Website
IPO Date
2023-01-30
DCF Diff
-1,291.01
DCF
2,003
Financial Ratios Every Investor Needs
Stock Dividend of AARTIPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2026-02-16 | February 16, 26 | 1.5 | 1.5 | 2026-02-16 | 2026-03-11 | |
| 2025-09-15 | September 15, 25 | 2.5 | 2.5 | 2025-09-15 | 2025-10-20 | |
| 2025-02-14 | February 14, 25 | 2.5 | 2.5 | 2025-02-14 | 2025-03-07 | |
| 2024-07-31 | July 31, 24 | 1 | 1 | 2024-07-31 | 2024-09-02 | |
| 2024-02-16 | February 16, 24 | 2 | 2 | 2024-02-19 | 2024-03-08 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,115.07 Cr | 1,127.88 Cr | 987.20 Cr | 0.4667 | 32.83 Cr | 163.13 Cr | 377.47 Cr | 272.40 Cr | 30.06 | 474.49 Cr | 0.1288 |
| 2024-03-31 | 1,815.51 Cr | 1,424.71 Cr | 390.80 Cr | 0.2153 | 8.37 Cr | 12.39 Cr | 281.49 Cr | 216.90 Cr | 23.93 | 390.94 Cr | 0.1195 |
| 2023-03-31 | 1,945.23 Cr | 1,531.36 Cr | 413.87 Cr | 0.2128 | 13.96 Cr | 14.44 Cr | 279.51 Cr | 193.49 Cr | 21.35 | 344.37 Cr | 0.0995 |
| 2022-03-31 | 1,192.03 Cr | 879.70 Cr | 312.33 Cr | 0.2620 | 7.16 Cr | 1.51 Cr | 164.83 Cr | 122.25 Cr | 13.49 | 197.84 Cr | 0.1026 |
| 2021-03-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0000 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -0.18 | 0.00 Cr | 0.0000 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 8.65 Cr | 2,906.41 Cr | 916.50 Cr | 1,989.9064 Cr | 413.12 Cr | 404.47 Cr | 587.58 Cr | 1,410.70 Cr | 0.00 Cr | 0.00 Cr | 29.24 Cr | 657.0495 Cr |
| 2024-03-31 | 23.63 Cr | 2,582.11 Cr | 825.07 Cr | 1,757.0400 Cr | 285.25 Cr | 261.62 Cr | 642.86 Cr | 1,105.45 Cr | 0.00 Cr | 0.00 Cr | 42.63 Cr | 694.3891 Cr |
| 2023-03-31 | 12.12 Cr | 2,244.02 Cr | 685.54 Cr | 1,558.4866 Cr | 215.31 Cr | 203.19 Cr | 602.04 Cr | 988.57 Cr | 0.00 Cr | 1.32 Cr | 41.38 Cr | 600.6234 Cr |
| 2022-03-31 | 83.27 Cr | 2,039.90 Cr | 653.42 Cr | 1,386.4778 Cr | 341.40 Cr | 258.13 Cr | 475.45 Cr | 945.31 Cr | 0.00 Cr | 0.00 Cr | 32.23 Cr | 580.6649 Cr |
| 2021-03-31 | 0.25 Cr | 0.25 Cr | 0.02 Cr | 0.2267 Cr | 0.02 Cr | -0.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0219 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 331.5615 Cr | -413.8977 Cr | 65.4350 Cr | -70.4759 Cr | -16.9012 Cr | 6.7337 Cr | -443.8784 Cr | 272.4048 Cr | 127.8608 Cr | -31.7191 Cr | 55.2790 Cr |
| 2024-03-31 | 216.3546 Cr | -214.5644 Cr | 9.7235 Cr | 17.5695 Cr | 11.5137 Cr | 23.6349 Cr | -155.6042 Cr | 216.9020 Cr | 49.9934 Cr | -18.1252 Cr | -39.6600 Cr |
| 2023-03-31 | 250.1154 Cr | -157.8030 Cr | -163.4646 Cr | 130.4585 Cr | -71.1522 Cr | 12.1212 Cr | -119.6569 Cr | 260.7747 Cr | -124.2877 Cr | -18.1252 Cr | -126.6600 Cr |
| 2022-03-31 | -43.7038 Cr | -138.7389 Cr | 260.3834 Cr | -184.8558 Cr | 83.0234 Cr | 83.2734 Cr | -141.1520 Cr | 155.3804 Cr | 272.3422 Cr | 0.0000 Cr | -55.9920 Cr |
| 2021-03-31 | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 0.2500 Cr | 0.0000 Cr | -0.0046 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 432.27 Cr | 172.66 Cr | 259.62 Cr | 0.6006 | 73.69 Cr | 47.96 Cr | 5.29 | 104.07 Cr | 0.1109 |
| 2025-09-30 | 418.33 Cr | 277.96 Cr | 140.38 Cr | 0.3356 | 49.95 Cr | 27.92 Cr | 3.08 | 74.77 Cr | 0.0667 |
| 2025-06-30 | 386.19 Cr | 169.41 Cr | 216.79 Cr | 0.5613 | 72.45 Cr | 49.50 Cr | 5.46 | 95.04 Cr | 0.1282 |
| 2025-03-31 | 563.78 Cr | 278.75 Cr | 285.03 Cr | 0.5056 | 122.81 Cr | 88.34 Cr | 9.75 | 144.54 Cr | 0.1567 |
| 2024-12-31 | 537.78 Cr | 275.31 Cr | 262.47 Cr | 0.4881 | 105.57 Cr | 73.99 Cr | 8.16 | 133.64 Cr | 0.1376 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 55.56 Cr | 0.00 Cr | 55.56 Cr | 470.63 Cr | 620.59 Cr | 1,326.30 Cr | 1,560.96 Cr | 3,265.90 Cr | 1,219.70 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 56.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,989.91 Cr |
| 2025-03-31 | 8.65 Cr | 49.12 Cr | 56.21 Cr | 576.42 Cr | 587.58 Cr | 1,322.17 Cr | 1,410.70 Cr | 2,906.41 Cr | 916.50 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 99.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,856.73 Cr |
| 2024-09-30 | 41.35 Cr | 58.16 Cr | 99.51 Cr | 434.38 Cr | 719.80 Cr | 1,376.67 Cr | 1,228.35 Cr | 2,776.51 Cr | 919.79 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 49.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 88.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 73.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 54.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 55.45 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
President of R&D
S. Patravale
Gender: Not Specified
Year Born:
Head of Operations & Manufacturing, CDMO & CMO
Naidu
Gender: male
Year Born:
Head of Business Development & Direct Procurement
Jasmin Mehta
Gender: male
Year Born:
Company Secretary & Compliance Officer
Jeevan Bhargav Mondkar
Gender: male
Year Born:
MD & Director
Narendra Jagannath Salvi
Gender: male
Year Born: 1964
Chief Financial Officer
Piyush Lakhani
Gender: male
Year Born:
Head of API Export Regulated and R&D Management
Sachin Patil
Gender: male
Year Born:
Chief Technology Officer
Shrihari S. Mane
Gender: male
Year Born:
Senior General Manager of HR & Admin
Sudhakar Shetty
Gender: male
Year Born:
Vice Chairperson & MD
Hetal Gogri Gala
Gender: female
Year Born: 1975
FAQs about Aarti Pharmalabs Limited
Who is the CEO of the company?
The CEO is Hetal Gogri Gala.
What is the current market price of the stock?
The current price is ₹705.75.
What is the 52-week price range?
The range is ₹574.45-971.
What is the market capitalization of the company?
The market capitalization is ₹6,397.43 crores.
What is the dividend yield?
The dividend yield is 0.57%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 29.94.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Aarti Pharmalabs Limited (ISIN: INE0LRU01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹6,397.43 crores and an average daily volume of 199,188 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹4.